BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23756255)

  • 1. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy.
    Wei Q; Shui Y; Zheng S; Wester K; Nordgren H; Nygren P; Glimelius B; Carlsson J
    Oncol Rep; 2011 Jan; 25(1):3-11. PubMed ID: 21109951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
    Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
    Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.
    Wei Q; Sheng L; Shui Y; Hu Q; Nordgren H; Carlsson J
    Ann Surg Oncol; 2008 Apr; 15(4):1193-201. PubMed ID: 18172732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
    Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
    Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
    J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
    Sun M; Behrens C; Feng L; Ozburn N; Tang X; Yin G; Komaki R; Varella-Garcia M; Hong WK; Aldape KD; Wistuba II
    Clin Cancer Res; 2009 Aug; 15(15):4829-37. PubMed ID: 19622585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
    Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
    J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.
    Wei Q; Chen L; Sheng L; Nordgren H; Wester K; Carlsson J
    Int J Oncol; 2007 Sep; 31(3):493-9. PubMed ID: 17671674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer.
    Tomasich E; Steindl A; Paiato C; Hatziioannou T; Kleinberger M; Berchtold L; Puhr R; Hainfellner JA; Müllauer L; Widhalm G; Eckert F; Bartsch R; Heller G; Preusser M; Berghoff AS
    Clin Cancer Res; 2023 Aug; 29(16):3225-3236. PubMed ID: 37036472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
    Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H
    Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.
    Ekberg T; Nestor M; Engström M; Nordgren H; Wester K; Carlsson J; Anniko M
    Int J Oncol; 2005 May; 26(5):1177-85. PubMed ID: 15809707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
    Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
    Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Cappuzzo F
    Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.